DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Natalie S Callander,Vincent Ribrag,Paul G Richardson,Ajay K Nooka,Kevin Song,Katarina Uttervall,Monique C Minnema,Katja Weisel,Hang Quach,Chang-Ki Min,Marc S Ballas,Xiaofang Li,Nirav Ratia,Morrys Kaisermann,Beata Holkova,Suzanne Trudel

doi:10.1182/blood-2021-152662

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Natalie S Callander, Vincent Ribrag + Show 14 more

Open Access

https://doi.org/10.1182/blood-2021-152662

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 7

Affiliation: University of Wisconsin–Madison, Institut Gustave Roussy, Dana-Farber Cancer Institute, Emory University, Vancouver General Hospital, Karolinska University Hospital, University Medical Center Utrecht, University Medical Center Hamburg-Eppendorf, University of Melbourne, Seoul St. Mary's Hospital, GlaxoSmithKline (United States), Providence College, GlaxoSmithKline (United Kingdom), Princess Margaret Cancer Centre

#Equity Holder In Publicly-traded Company #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.